You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMephentermine
Accession NumberDB01365
TypeSmall Molecule
GroupsApproved
DescriptionA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
Structure
Thumb
Synonyms
Mephentermine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Wyamine Sulfate Injection Liq 30mg/mlLiquid30 mgIntramuscular; IntravenousWyeth Ayerst Canada Inc.1994-12-311998-12-15Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
WyamineNot Available
WyfenterminaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mephentermine sulfate
1212-72-2
Thumb
  • InChI Key: DNKCFBJMFIUNRS-UHFFFAOYSA-N
  • Monoisotopic Mass: 424.239578821
  • Average Mass: 424.6
DBSALT001074
Categories
UNIITEZ91L71V4
CAS number100-92-5
WeightAverage: 163.2594
Monoisotopic: 163.136099549
Chemical FormulaC11H17N
InChI KeyRXQCGGRTAILOIN-UHFFFAOYSA-N
InChI
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
IUPAC Name
methyl(2-methyl-1-phenylpropan-2-yl)amine
SMILES
CNC(C)(C)CC1=CC=CC=C1
Pharmacology
IndicationUsed to maintain blood pressure in hypotensive states.
Structured Indications Not Available
PharmacodynamicsMephentermine is a sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
Mechanism of actionMephentermine is an alpha adrenergic receptor agonist, but also acts indirectly by releasing endogenous norepinephrine. Cardiac output and systolic and diastolic pressures are usually increased. A change in heart rate is variable, depending on the degree of vagal tone. Sometimes the net vascular effect may be vasodilation. Large doses may depress the myocardium or produce central nervous system (CNS) effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha adrenergic receptorProtein groupyes
agonist
Humannot applicabledetails
Beta adrenergic receptorProtein groupunknown
agonist
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, by N-demethylation and then p-hydroxylation.

Route of eliminationNot Available
Half life17 to 18 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Mephentermine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Mephentermine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Mephentermine.Approved
AcrivastineMephentermine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineMephentermine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilMephentermine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
AlimemazineMephentermine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolMephentermine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the vasopressor activities of Mephentermine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Mephentermine.Approved, Investigational
AmitriptylineAmitriptyline may increase the vasopressor activities of Mephentermine.Approved
Ammonium chlorideThe serum concentration of Mephentermine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Mephentermine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mephentermine.Approved, Illicit
AntazolineMephentermine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Mephentermine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Mephentermine.Approved
AstemizoleMephentermine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Mephentermine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Mephentermine.Vet Approved
AzatadineMephentermine may decrease the sedative activities of Azatadine.Approved
AzelastineMephentermine may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Mephentermine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Mephentermine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.Approved, Illicit
Benzylpenicilloyl PolylysineMephentermine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BezitramideMephentermine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Mephentermine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Mephentermine.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Mephentermine.Approved, Investigational
BromperidolBromperidol may decrease the stimulatory activities of Mephentermine.Investigational
BrompheniramineMephentermine may decrease the sedative activities of Brompheniramine.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Mephentermine.Investigational
BuclizineMephentermine may decrease the sedative activities of Buclizine.Approved
BuprenorphineMephentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic AcidMephentermine may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolMephentermine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Mephentermine.Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
CarbinoxamineMephentermine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilMephentermine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Mephentermine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Mephentermine.Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Mephentermine is combined with Celiprolol.Approved, Investigational
CetirizineMephentermine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineMephentermine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineMephentermine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineMephentermine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
CimetidineMephentermine may decrease the sedative activities of Cimetidine.Approved
CinnarizineMephentermine may decrease the sedative activities of Cinnarizine.Approved
ClemastineMephentermine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineClomipramine may increase the vasopressor activities of Mephentermine.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Mephentermine.Approved
CodeineMephentermine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Mephentermine.Approved
CyclizineMephentermine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Mephentermine.Approved
CyproheptadineMephentermine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Mephentermine.Approved
DesipramineDesipramine may increase the vasopressor activities of Mephentermine.Approved
DesloratadineMephentermine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Mephentermine.Approved
DexbrompheniramineMephentermine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleateMephentermine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideMephentermine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMephentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineMephentermine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
DihydrocodeineMephentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Mephentermine.Approved
DihydroetorphineMephentermine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMephentermine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMephentermine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneMephentermine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineMephentermine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineMephentermine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateMephentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mephentermine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Mephentermine.Approved
DosulepinDosulepin may increase the vasopressor activities of Mephentermine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Mephentermine.Approved
DoxepinDoxepin may increase the vasopressor activities of Mephentermine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Doxofylline.Approved
DoxylamineMephentermine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEMephentermine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Mephentermine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Mephentermine.Approved
EbastineMephentermine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Mephentermine.Investigational
EmedastineMephentermine may decrease the sedative activities of Emedastine.Approved
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Mephentermine.Approved
EpinastineMephentermine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Mephentermine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Mephentermine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Mephentermine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Mephentermine.Approved
EsmirtazapineEsmirtazapine may increase the vasopressor activities of Mephentermine.Investigational
EthopropazineMephentermine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephentermine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Withdrawn
EthylmorphineMephentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Etilefrine.Withdrawn
EtorphineMephentermine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineMephentermine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Mephentermine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Mephentermine.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.Approved, Illicit, Investigational, Vet Approved
FexofenadineMephentermine may decrease the sedative activities of Fexofenadine.Approved
FlunarizineMephentermine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Mephentermine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Mephentermine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Mephentermine.Approved, Vet Approved
GuanethidineThe serum concentration of Mephentermine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Mephentermine.Approved
HeroinMephentermine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Mephentermine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Mephentermine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Mephentermine.Approved
HydrocodoneMephentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneMephentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Mephentermine is combined with Hydroxyamphetamine hydrobromide.Approved
HydroxyzineMephentermine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Mephentermine.Approved
ImipramineImipramine may increase the vasopressor activities of Mephentermine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Mephentermine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Mephentermine.Approved
Ioflupane I-123Mephentermine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Mephentermine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Mephentermine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Mephentermine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.Approved
IsothipendylMephentermine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Isoxsuprine.Approved, Withdrawn
Kct 0809Mephentermine may decrease the sedative activities of Kct 0809.Investigational
KetobemidoneMephentermine may increase the analgesic activities of Ketobemidone.Approved
KetotifenMephentermine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Mephentermine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LabetalolLabetalol may decrease the vasoconstricting activities of Mephentermine.Approved
LevocabastineMephentermine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineMephentermine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateMephentermine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Mephentermine.Approved
LevorphanolMephentermine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Mephentermine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Mephentermine.Approved
LodoxamideMephentermine may decrease the sedative activities of Lodoxamide.Approved
LofentanilMephentermine may increase the analgesic activities of Lofentanil.Illicit
LoratadineMephentermine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Mephentermine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Mephentermine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Mephentermine.Withdrawn
MeclizineMephentermine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Mephentermine.Approved
MepyramineMephentermine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineMephentermine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Mephentermine.Approved, Investigational
MethadoneMephentermine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateMephentermine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methamphetamine.Approved, Illicit
MethapyrileneMephentermine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Mephentermine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Mephentermine.Investigational
MetiamideMephentermine may decrease the sedative activities of Metiamide.Experimental
MianserinMephentermine may decrease the sedative activities of Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Mephentermine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Mephentermine.Approved
MinaprineMinaprine may increase the hypertensive activities of Mephentermine.Approved
MirtazapineMirtazapine may increase the vasopressor activities of Mephentermine.Approved
MizolastineMephentermine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Mephentermine.Approved
MolindoneMolindone may decrease the stimulatory activities of Mephentermine.Approved
MorphineMephentermine may increase the analgesic activities of Morphine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Mephentermine.Approved, Investigational
NalbuphineMephentermine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Mephentermine.Withdrawn
NizatidineMephentermine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Mephentermine.Approved
NormethadoneMephentermine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the vasopressor activities of Mephentermine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Mephentermine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Mephentermine.Approved, Investigational
OlopatadineMephentermine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Mephentermine.Approved
OpipramolOpipramol may increase the vasopressor activities of Mephentermine.Investigational
OpiumMephentermine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Mephentermine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Mephentermine.Investigational
OxycodoneMephentermine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.Approved
OxymorphoneMephentermine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Mephentermine.Approved
PargylinePargyline may increase the hypertensive activities of Mephentermine.Approved
PemirolastMephentermine may decrease the sedative activities of Pemirolast.Approved
PentazocineMephentermine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Mephentermine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Mephentermine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Mephentermine.Approved
PethidineMephentermine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Mephentermine.Approved
PhenindamineMephentermine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Mephentermine.Withdrawn
PheniramineMephentermine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Mephentermine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Mephentermine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Mephentermine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mephentermine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Mephentermine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Mephentermine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Mephentermine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Mephentermine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Mephentermine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Mephentermine.Approved
PiritramideMephentermine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Mephentermine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Mephentermine.Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Mephentermine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Procaterol.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
PromethazineMephentermine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Mephentermine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Mephentermine.Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Mephentermine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Mephentermine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Mephentermine.Investigational
RanitidineMephentermine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Mephentermine.Approved
RemifentanilMephentermine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Mephentermine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Mephentermine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Mephentermine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine.Approved
Roxatidine acetateMephentermine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Mephentermine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Mephentermine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
SilodosinSilodosin may decrease the vasoconstricting activities of Mephentermine.Approved
Spaglumic AcidMephentermine may decrease the sedative activities of Spaglumic Acid.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Mephentermine.Approved
SufentanilMephentermine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Mephentermine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
TapentadolMephentermine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Mephentermine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Mephentermine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.Approved
TerfenadineMephentermine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneMephentermine may decrease the sedative activities of Tesmilifene.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tetryzoline.Approved
ThioproperazineThioproperazine may decrease the stimulatory activities of Mephentermine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Mephentermine.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Mephentermine.Approved
ThonzylamineMephentermine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the vasopressor activities of Mephentermine.Approved
TiaprideTiapride may decrease the stimulatory activities of Mephentermine.Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Mephentermine.Approved
TramadolMephentermine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastMephentermine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephentermine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Mephentermine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Mephentermine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Mephentermine.Experimental
TrimipramineTrimipramine may increase the vasopressor activities of Mephentermine.Approved
TripelennamineMephentermine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineMephentermine may decrease the sedative activities of Triprolidine.Approved
TyramineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineVenlafaxine may increase the tachycardic activities of Mephentermine.Approved
Vitamin CThe serum concentration of Mephentermine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Mephentermine.Approved
ZotepineZotepine may decrease the stimulatory activities of Mephentermine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Mephentermine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01CA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9664
Caco-2 permeable+0.7962
P-glycoprotein substrateNon-substrate0.5711
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.775
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateSubstrate0.7109
CYP450 3A4 substrateNon-substrate0.5507
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8388
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.979
CarcinogenicityNon-carcinogens0.8079
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.8952 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9804
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous30 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP2.54ALOGPS
logP2.52ChemAxon
logS-2.5ALOGPS
pKa (Strongest Basic)10.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.12 m3·mol-1ChemAxon
Polarizability19.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.87 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
  2. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:56 / Updated on December 08, 2016 11:46